NSCLC
These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients.
These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and <span class="gene" id="21791641-10-113-117">EGFR</span> inhibitors may represent an effective therapy for these subsets of <span class="disease" id="21791641-10-185-190">NSCLC</span> patients.